This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
BrainsWay is continuously seeking to expand its platform, achieving outcomes that surpass traditional medical solutions. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medical studies, BrainsWay represents the next-generation of treatment options for Major Depression and OCD.
Well-positioned as a leader in this rapidly-expanding field, BrainsWay is changing the future of mental health.
*See response and remission rates in the MDD and OCD treatment pages
OF POPULATION IS COVERED BY REIMBURSEMENT